Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.

<h4>Background</h4>Countries are currently progressing towards the elimination of new paediatric HIV infections by 2015. WHO published new consolidated guidelines in June 2013, which now recommend either 'Antiretroviral drugs (ARVs) for women living with HIV during pregnancy and bre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Naoko Ishikawa, Takuro Shimbo, Shinsuke Miyano, Izukanji Sikazwe, Albert Mwango, Massimo N Ghidinelli, Gardner Syakantu
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
R
Q
Acceso en línea:https://doaj.org/article/f87a6f95dde64fef9b6f48ad7eb8b744
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f87a6f95dde64fef9b6f48ad7eb8b744
record_format dspace
spelling oai:doaj.org-article:f87a6f95dde64fef9b6f48ad7eb8b7442021-11-18T08:29:17ZHealth outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.1932-620310.1371/journal.pone.0090991https://doaj.org/article/f87a6f95dde64fef9b6f48ad7eb8b7442014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24604067/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Countries are currently progressing towards the elimination of new paediatric HIV infections by 2015. WHO published new consolidated guidelines in June 2013, which now recommend either 'Antiretroviral drugs (ARVs) for women living with HIV during pregnancy and breastfeeding (Option B)' or 'Lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding women living with HIV (Option B+)', while de facto phasing out Option A. This study examined health outcomes and cost impact of the shift to WHO 2013 recommendations in Zambia.<h4>Methods</h4>A decision analytic model was developed based on the national health system perspective. Estimated risk and number of cases of HIV transmission to infants and to serodiscordant partners, and proportions of HIV-infected pregnant women with CD4 count of ≤350 cells/mm3 to initiate ART were compared between 2010 Option A and the 2013 recommendations. Total costs of prevention of mother-to-child transmission of HIV (PMTCT) services per annual cohort of pregnant women, incremental cost-effectiveness ratio (ICER) per infection averted and quality-adjusted life-year (QALY) gained were examined.<h4>Results</h4>Our analysis suggested that the shift from 2010 Option A to the 2013 guidelines would result in a 33% reduction of the risk of HIV transmission among exposed infants. The risk of transmission to serodiscordant partners for a period of 24 months would be reduced by 72% with 'ARVs during pregnancy and breastfeeding' and further reduced by 15% with 'Lifelong ART'. The probability of HIV-infected pregnant women to initiate ART would increase by 80%. It was also suggested that while the shift would generate higher PMTCT costs, it would be cost-saving in the long term as it spares future treatment costs by preventing infections in infants and partners.<h4>Conclusion</h4>The shift to the WHO 2013 guidelines in Zambia would positively impact health of family and save future costs related to care and treatment.Naoko IshikawaTakuro ShimboShinsuke MiyanoIzukanji SikazweAlbert MwangoMassimo N GhidinelliGardner SyakantuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 3, p e90991 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Naoko Ishikawa
Takuro Shimbo
Shinsuke Miyano
Izukanji Sikazwe
Albert Mwango
Massimo N Ghidinelli
Gardner Syakantu
Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
description <h4>Background</h4>Countries are currently progressing towards the elimination of new paediatric HIV infections by 2015. WHO published new consolidated guidelines in June 2013, which now recommend either 'Antiretroviral drugs (ARVs) for women living with HIV during pregnancy and breastfeeding (Option B)' or 'Lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding women living with HIV (Option B+)', while de facto phasing out Option A. This study examined health outcomes and cost impact of the shift to WHO 2013 recommendations in Zambia.<h4>Methods</h4>A decision analytic model was developed based on the national health system perspective. Estimated risk and number of cases of HIV transmission to infants and to serodiscordant partners, and proportions of HIV-infected pregnant women with CD4 count of ≤350 cells/mm3 to initiate ART were compared between 2010 Option A and the 2013 recommendations. Total costs of prevention of mother-to-child transmission of HIV (PMTCT) services per annual cohort of pregnant women, incremental cost-effectiveness ratio (ICER) per infection averted and quality-adjusted life-year (QALY) gained were examined.<h4>Results</h4>Our analysis suggested that the shift from 2010 Option A to the 2013 guidelines would result in a 33% reduction of the risk of HIV transmission among exposed infants. The risk of transmission to serodiscordant partners for a period of 24 months would be reduced by 72% with 'ARVs during pregnancy and breastfeeding' and further reduced by 15% with 'Lifelong ART'. The probability of HIV-infected pregnant women to initiate ART would increase by 80%. It was also suggested that while the shift would generate higher PMTCT costs, it would be cost-saving in the long term as it spares future treatment costs by preventing infections in infants and partners.<h4>Conclusion</h4>The shift to the WHO 2013 guidelines in Zambia would positively impact health of family and save future costs related to care and treatment.
format article
author Naoko Ishikawa
Takuro Shimbo
Shinsuke Miyano
Izukanji Sikazwe
Albert Mwango
Massimo N Ghidinelli
Gardner Syakantu
author_facet Naoko Ishikawa
Takuro Shimbo
Shinsuke Miyano
Izukanji Sikazwe
Albert Mwango
Massimo N Ghidinelli
Gardner Syakantu
author_sort Naoko Ishikawa
title Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
title_short Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
title_full Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
title_fullStr Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
title_full_unstemmed Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
title_sort health outcomes and cost impact of the new who 2013 guidelines on prevention of mother-to-child transmission of hiv in zambia.
publisher Public Library of Science (PLoS)
publishDate 2014
url https://doaj.org/article/f87a6f95dde64fef9b6f48ad7eb8b744
work_keys_str_mv AT naokoishikawa healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
AT takuroshimbo healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
AT shinsukemiyano healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
AT izukanjisikazwe healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
AT albertmwango healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
AT massimonghidinelli healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
AT gardnersyakantu healthoutcomesandcostimpactofthenewwho2013guidelinesonpreventionofmothertochildtransmissionofhivinzambia
_version_ 1718421779765002240